Home › Keratoconus › NCT07400952
Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus
RecruitingPhase 2
Multicenter, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus
Who can join
Ages 18 to 55 · All sexes
Full eligibility criteria
Inclusion Criteria: * Be ≥ 18 and ≤ 55 years of age * Diagnosis of keratoconus in the study eye Exclusion Criteria: * Pregnant, lactating or planning a pregnancy * Currently enrolled, or within 30 days prior to Screening were enrolled, in another investigational drug or device trial
About the study
Multi-center, parallel-group, placebo-controlled trial designed to assess the safety and efficacy of twice-daily topically administered GLK-221 Ophthalmic Solution in subjects with keratoconus.
What is being tested
- GLK-221 Ophthalmic Solution (drug)
- Placebo Ophthalmic Solution (drug)
Sponsor: Glaukos Corporation · Participants: 100 · Started: Dec 23, 2025
Contact the study team
- Study Manager · Phone: 949-739-8749
Official record on ClinicalTrials.gov — NCT07400952
Locations in the U.S.
| Ohio | Glaukos Clinical Study Site, Westerville |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.